Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2) - Trial NCT05650164
Access comprehensive clinical trial information for NCT05650164 through Pure Global AI's free database. This phase not specified trial is sponsored by Pfizer and is currently Recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Pfizer
Timeline & Enrollment
N/A
Jan 25, 2023
Apr 30, 2023
Primary Outcome
Description of patient characteristics at baseline
Summary
This study is a multicenter, non-interventional, retrospective, medical chart review of
 patients with metastatic renal cell cancer(mRCC) treated with avelumab plus axitinib as a
 first-line therapy in Japan between 20 December 2019 and 17 October 2022. All decisions
 regarding clinical management and treatment of the participating patients were made by the
 investigator as part of standard care in real-world clinical setting and were not contingent
 upon the patient's participation in the study. Data will be collected if available per study
 site.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05650164
Non-Device Trial